Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment

被引：6
|
作者：
Carbone, Antonino [1 ]
Gloghini, Annunziata [2 ]
Pruneri, Giancarlo [2 ]
Dolcetti, Riccardo [3 ]
机构：
[1] IRCCS, Ctr Riferimento Oncol Aviano CRO, Aviano, Italy
[2] Ist Nazl Tumori Milano, Fdn IRCCS, Dept Diagnost Pathol & Lab Med, Milan, Italy
[3] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia
来源：
CANCER MEDICINE | 2019年 / 8卷 / 06期
关键词：
checkpoint blockade; classic Hodgkin lymphoma; immune escape; multiplex immunohistochemistry; resistance; tumor microenvironment; CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; SUPPRESSOR-CELLS; ANALYSIS REVEALS; STERNBERG CELLS; PHASE-II; BLOCKADE; NIVOLUMAB; REED; PEMBROLIZUMAB;
D O I：
10.1002/cam4.2168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immune checkpoint-blocking antibodies have therapeutic activity against relapsed or progressive classic Hodgkin lymphoma (cHL), but Hodgkin Reed-Sternberg cells can develop resistance to this therapy via multiple mechanisms. To improve the efficacy of immune checkpoint blockade, we need a more precise understanding of the immune escape mechanisms active in individual cHL patients, and this requires a detailed characterization of immune cell populations in the tumor microenvironment. These cell-cell interactions can now be studied by multiplex immunohistochemistry coupled to digital image analysis. This method should allow the identification of actionable target molecules mediating resistance to immune checkpoint inhibitors in individual cHL patients, thereby favoring the implementation of personalized therapies.
引用
收藏
页码：3012 / 3016
页数：5
相关论文
共 50 条
  • [31] Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment
    Gorris, Mark A. J.
    Halilovic, Altuna
    Rabold, Katrin
    van Duffelen, Anne
    Wickramasinghe, Iresha N.
    Verweij, Dagmar
    Wortel, Inge M. N.
    Textor, Johannes C.
    de Vries, I. Jolanda M.
    Figdor, Carl G.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01): : 347 - 354
  • [32] PD-L1 Immunohistochemistry Highlights Bone Marrow Involvement by Classic Hodgkin Lymphoma in Staging Biopsies: Implications for Diagnosis and Tumor Microenvironment Alterations
    Xing, Wei
    Mai, Nicholas
    Dresser, Karen
    Chen, Benjamin J.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (05) : 356 - 363
  • [33] New key factors in the outcome of Hodgkin's lymphoma cases: Tumor microenvironment and mitotic checkpoint
    Garcia, JF
    Sanchez-Aguilera, A
    Montalbn, C
    Dominguez, P
    Sanchez-Verde, L
    Morente, MM
    Garcia-Cosio, M
    Bellas, C
    Romagosa, V
    Menarguez, J
    Mestre, MJ
    Fresno, MF
    Piris, MA
    MODERN PATHOLOGY, 2006, 19 : 226A - 226A
  • [34] New key factors in the outcome of Hodgkin's lymphoma cases: Tumor microenvironment and mitotic checkpoint
    Garcia, JF
    Sanchez-Aguilera, A
    Montalban, C
    Dominguez, P
    Sanchez-Verde, L
    Morente, MM
    Garcia-Cosio, M
    Bellas, C
    Romagosa, V
    Menarguez, J
    Mestre, MJ
    Fresno, MF
    Piris, MA
    LABORATORY INVESTIGATION, 2006, 86 : 226A - 226A
  • [35] Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
    Carreau, Nicole A.
    Armand, Philippe
    Merryman, Reid W.
    Advani, Ranjana H.
    Spinner, Michael A.
    Herrera, Alex F.
    Ramchandren, Radhakrishnan
    Hamid, Muhammad S.
    Assouline, Sarit
    Santiago, Raoul
    Wagner-Johnston, Nina
    Paul, Suman
    Svoboda, Jakub
    Bair, Steven M.
    Barta, Stefan K.
    Nathan, Sunita
    Karmali, Reem
    Torka, Pallawi
    David, Kevin
    Lansigan, Frederick
    Persky, Daniel
    Godfrey, James
    Chavez, Julio C.
    Xia, Yuhe
    Diefenbach, Catherine
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (01) : 44 - 51
  • [36] Successful Treatment of Paraneoplastic Cholestasis in Relapsed/Refractory Hodgkin Lymphoma With Bridging Therapy and Checkpoint Blockade
    Peringeth, Gopisree
    Torka, Pallawi
    Wong, Jerry
    Hernandez-Ilizaliturri, Francisco J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (06): : E316 - E319
  • [37] Characterization of checkpoint inhibitors in the tumor microenvironment (TME) and peripheral blood in endemic Burkitt Lymphoma
    Saikumar-Lakshmi, Priya
    Oduor, Cliff
    Forconi, Catherine
    Marsh, Patrick
    Ong'echa, John Michael
    Bailey, Jeffrey
    Moormann, Ann
    CANCER RESEARCH, 2020, 80 (14) : 51 - 51
  • [38] Patterns of Progression on Immune Checkpoint Inhibitor Therapy for Relapsed Hodgkin Lymphoma: Implications for the Potential Role of Radiation Therapy
    Burlile, J. F.
    Breen, W.
    Hwang, S. R.
    Higgins, A. S.
    Nedved, A. N.
    Harmsen, W. S.
    Witzig, T.
    Micallef, I. N.
    Hoppe, B. S.
    Habermann, T. M.
    Thanarajasingam, G.
    Johnston, P.
    Inwards, D. J.
    Bennani, N.
    Peterson, J. L.
    Stish, B. J.
    Rule, W. G.
    Ansell, S. M.
    Lester, S. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S54 - S55
  • [39] Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy
    Burlile, Jessica F.
    Frechette, Kelsey M.
    Breen, William G.
    Hwang, Steven R.
    Higgins, Alexandra S.
    Nedved, Adrienne N.
    Harmsen, William S.
    Pulsipher, Sydney D.
    Witzig, Thomas E.
    Micallef, Ivana N.
    Hoppe, Bradford S.
    Habermann, Thomas M.
    Thanarajasingam, Gita
    Johnston, Patrick B.
    Inwards, David J.
    Bennani, N. Nora
    Peterson, Jennifer L.
    Stish, Bradley J.
    Rule, William G.
    Ansell, Stephen M.
    Lester, Scott C.
    BLOOD ADVANCES, 2024, 8 (05) : 1250 - 1257
  • [40] Successful restoration of checkpoint inhibitors efficacy after allogeneic hematopoietic cell transplant for classic Hodgkin lymphoma patients
    El Fakih, Riad
    Albabtain, Abdulwahab A.
    Alhayli, Saud
    Farhan, Khawlah
    Rasheed, Walid
    Alshaibani, Alfadel
    Chaudhri, Naeem
    Aljurf, Mahmoud
    SEMINARS IN ONCOLOGY, 2023, 50 (3-5) : 76 - 85
12345